KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $18.4 million.

  • Sarepta Therapeutics' Depreciation & Amortization (CF) rose 88.15% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.7 million, marking a year-over-year increase of 28.68%. This contributed to the annual value of $37.7 million for FY2024, which is 15.03% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Depreciation & Amortization (CF) of $18.4 million as of Q3 2025, which was up 70.20% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Depreciation & Amortization (CF) ranged from a high of $18.4 million in Q3 2025 and a low of $8.4 million during Q2 2021.
  • In the last 3 years, Sarepta Therapeutics' Depreciation & Amortization (CF) had a median value of $10.8 million in 2023 and averaged $11.0 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Depreciation & Amortization (CF) decreased by 22.65% in 2024 and then spiked by 88.15% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Depreciation & Amortization (CF) stood at $10.1 million in 2021, then grew by 4.02% to $10.6 million in 2022, then climbed by 7.76% to $11.4 million in 2023, then declined by 8.06% to $10.5 million in 2024, then soared by 88.15% to $18.4 million in 2025.
  • Its Depreciation & Amortization (CF) was $18.4 million in Q3 2025, compared to $10.8 million in Q2 2025 and $10.0 million in Q1 2025.